|Bid||0.00 x 900|
|Ask||0.00 x 1400|
|Day's Range||4.06 - 5.75|
|52 Week Range||1.60 - 6.23|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2019 - Aug 16, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.40|
NeuBase Therapeutics, Inc. (Nasdaq:NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, announced today the completion of the merger between NeuBase Therapeutics, Inc. and Ohr Pharmaceutical, Inc. (“Ohr”) (OHRP) and associated financings. The combined Company’s common stock expects to begin trading on The Nasdaq Capital Market under the ticker symbol “NBSE” at the open of market trading on July 15, 2019.
Ohr Pharmaceutical, Inc. (“Ohr”) (OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc. (“NeuBase”) were approved by Ohr’s stockholders at a special meeting held on July 10, 2019. As previously announced on January 3, 2019, the proposed merger will create a public company under which the stockholders of NeuBase will become majority holders of the combined company. Upon closing of the transaction, the combined company will change its name to “NeuBase Therapeutics, Inc.”, and the NASDAQ trading symbol will become “NBSE”.
Ohr Pharmaceutical, Inc. (OHRP) (the “Company” or “Ohr”) reiterated the unanimous recommendation of its Board of Directors that stockholders vote “FOR” all of the proposals in connection with the proposed merger with NeuBase Therapeutics, Inc. at the Special Meeting of stockholders on July 10, 2019 (instructions on how to vote your shares are set forth below). It is important that all Ohr stockholders vote today.
NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.
Ohr Pharmaceutical, Inc. (OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019. "We continue to be excited by the opportunity to merge with NeuBase Therapeutics, a privately-held biotechnology company developing next-generation antisense therapeutics, which we believe offers the best opportunity to generate value for our stockholders. A special meeting for Ohr stockholders to vote on the proposed merger with NeuBase is currently on track to occur in the middle of calendar 2019," said Jason Slakter, M.D., chief executive officer of Ohr Pharmaceutical.
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Ohr Pharmaceutical, Inc. (“Ohr”) (OHRP) common stock in connection with the proposed merger of Ohr and NeuBase Therapeutics, Inc. (“NeuBase”) announced on January 3, 2019 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Ohr, its Board of Directors (the “Board”), and NeuBase, is captioned Wheby v. Ohr Pharmaceutical, Inc., Case No. 1:19-cv-00541 (D. Del.).
NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address rare genetic diseases, today announced that it has entered into definitive agreements for a $9.0 million financing that will close immediately prior to the closing of the company’s proposed merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The oversubscribed financing includes institutional and accredited investors, including participation by Cyto Ventures, a life sciences-focused venture capital fund affiliated with Dietrich Stephan, Ph.D., the CEO of NeuBase Therapeutics, and a member of Ohr’s board of directors. “We believe that the PATrOLTM platform, a 'next generation' antisense technology, is capable of addressing a multitude of rare genetic diseases which collectively affect approximately 400 million people worldwide, cause immense suffering and death and drive billions of dollars in healthcare costs annually.
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The tech stock market has been a hotbed of exciting conversation during the last few months as a result of word spreading about tech companies taking innovative approaches to create new technologies for the betterment of humankind. Stemming from the belief that consumers deserve to live life to the best of their ability, these tech companies have pioneered technological advancements in the areas of augmented reality, cloud computing, and countless others. ParcelPal Technology Inc (PTNYF) (PKG), Seelos Therapeutics Inc (SEEL), Renren Inc (RENN), and Ohr Pharmaceutical Inc (OHRP) represent 4 tech stocks on the rise on Wednesday.
NEW YORK, Feb. 21, 2019 -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has.
Ohr Pharmaceutical, Inc. (OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we announced the signing of a definitive agreement to merge with NeuBase Therapeutics, Inc., a privately-held biotechnology company, we have been working diligently to bring the proposed merger with NeuBase to our stockholders for a vote. “After reviewing various strategic alternatives for our business in 2018, we identified a merger with NeuBase as the best opportunity to generate value for our stockholders, based on their ongoing work to change the paradigm for treating rare genetic diseases with next generation, highly specific antisense oligonucleotide therapies.
NEW YORK , Feb. 14, 2019 /PRNewswire/ -- CAS Medical Systems, Inc. (CASM) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of CASM ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed merger of Ohr Pharmaceutical, Inc.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 23) China ...
Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (OHRP) announced today that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share. The Company's stockholders approved the reverse stock split at the Company's special meeting of shareholders held on January 18, 2019. The Company's common stock is expected to commence trading on a post-reverse stock split basis on February 4, 2019.
NEW YORK , Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , Jan. 9, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Ohr Pharmaceutical, Inc. ("OHRP" ...
NEW ORLEANS , Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger ...
Do you own shares of Ohr Pharmaceutical, Inc. (NASDAQ CM: OHRP)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (NASDAQ CM: OHRP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with NeuBase Therapeutics, Inc. (“NeuBase”).
NEW YORK, Jan. 04, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) on behalf.
A move that stands to fast-forward a new entry into Pittsburgh’s public company ranks by mid-year has benefits for both parties. South Side startup NeuBase Therapeutics’ top executive said a reverse merger with a struggling, publicly traded pharmaceutical company will speed delivery of its treatments for genetic diseases. Dietrich Stephan, NeuBase CEO and founder, said during a joint press conference on Thursday that the merger between NeuBase and Ohr Pharmaceutical Inc. “accelerates getting our technologies into the clinic for those who desperately need them.” For Ohr, which announced the pending deal on Wednesday, it culminates a year-long evaluation of strategic alternatives that Jason Slakter, president and CEO, described as “exhausting.” But he believes the merger opens opportunities to create value for stockholders.
NEW YORK, Jan. 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ohr Pharmaceutical, Inc. (“Ohr” or.
PITTSBURGH, Jan. 4, 2019 /PRNewswire/ -- LifeX™ today announced that its portfolio company NeuBase Therapeutics, Inc. has entered into a definitive merger agreement with Ohr Pharmaceutical, Inc. (OHRP) and that Dietrich A. Stephan, Ph.D., the former chief executive officer of LifeX, will lead the combined company as its CEO. In less than a year, NeuBase has gone from an idea to a company with a clear path to a NASDAQ list, validating the LifeX approach of quickly translating technology from the bench to the bedside.
CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...
Ohr Pharmaceutical, Inc. (“Ohr”) (OHRP) announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc. (“NeuBase”), under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.